Strategic partnerships LifeNome already collaborates with Fortune 500 partners and major brands like World Economic Forum, PepsiCo, and Abbott. This signals openness to enterprise partnerships and co-development of health solutions, presenting a sales path focused on large-scale integration, enterprise wellness programs, and insurance/PHM collaborations.

Enterprise wellness With a global footprint across 15+ countries and a platform used by over 650,000 individuals, there is a clear opportunity to expand into employer health initiatives, corporate wellness programs, and insurance risk assessment services leveraging LifeNome’s AI-driven prevention and genomics insights.

Growth through AI Core offerings center on AI-driven disease risk detection, precision prevention, and multi-omics. This positions LifeNome to target health insurers, pharma partners, and healthcare providers seeking advanced risk stratification, preventive care programs, and data-backed wellness interventions.

Product breadth The portfolio includes maternal & family health, biological longevity, and personalized nutrition. Sales opportunities exist to plug these modules into hospitals, clinics, and telehealth platforms, as well as to support maternity and nutrition initiatives within insurer networks.

Funding and momentum Historical grants and accelerator wins (including a $100k + $100k grants and new product launches like 9Moons) indicate a track record of rapid product development and external validation, which can be leveraged in customer ROI discussions and to shorten procurement cycles.